Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Placing

12 Nov 2009 07:00

RNS Number : 3824C
Futura Medical PLC
12 November 2009
 



For immediate release 

12 November 2009

Futura Medical plc

("Futura" or "the Company")

Placing

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce a Placing by Nomura Code Securities Limited in which gross proceeds of £1.46 million are being raised through the issue of 4,864,471 new ordinary shares of 0.2 pence each in Futura ("Ordinary Shares"), to new and existing institutional and other investors at a price of 30 pence per share The Placing represents approximately 7.8% of the Company's issued share capital.

The net proceeds of the fundraising will be used to provide additional working capital, to support the regulatory approval of CSD500, to progress the Company's developmental projects, as well as to evaluate some early stage research leads. Further it is expected a strengthened balance sheet will assist in the Company's out-licensing negotiations with pharmaceutical and other partners. 

The Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange and it is anticipated that trading of the Ordinary Shares will commence on AIM at 8:00am on 18 November 2009. 

Futura's total issued shared capital following the admission of the Ordinary Shares will be 67,483,311. The total number of voting rights in the Company will be 67,483,311.

James Barder, Futura's Chief Executive, said: "We are pleased with the support of new and existing investors in this Placing, which will allow us to progress our exciting pipeline of products and give us the ability to capture more of their long term value. We continue to manage our costs carefully and intend to exploit our low cost business model to progress those projects that we believe have significant upside. Having a strengthened balance sheet will undoubtedly be of assistance in our current out-licensing discussions."

For any further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

mail to: james.barder@futuramedical.co.uk

www.futuramedical.co.uk 

Nomura Code Securities Limited 

Charles Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

For media enquiries please contact: 

Buchanan Communications

Mark Court / Stasa Filiplic / Jennie Spivey

Tel: +44 (0) 20 7466 5000

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEKFLFFKFBFFBQ
Date   Source Headline
24th Jun 20207:00 amRNSTrading Statement
9th Jun 20202:06 pmRNSSecond Price Monitoring Extn
9th Jun 20202:00 pmRNSPrice Monitoring Extension
1st Jun 20207:00 amRNSBlock listing Interim Review
28th May 20204:40 pmRNSSecond Price Monitoring Extn
28th May 20204:35 pmRNSPrice Monitoring Extension
19th May 20204:40 pmRNSSecond Price Monitoring Extn
19th May 20204:35 pmRNSPrice Monitoring Extension
19th May 20202:00 pmRNSPrice Monitoring Extension
19th May 202011:05 amRNSSecond Price Monitoring Extn
19th May 202011:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSNotice of AGM and Annual Report
6th May 202011:00 amRNSPrice Monitoring Extension
5th May 20204:36 pmRNSPrice Monitoring Extension
22nd Apr 20203:13 pmRNSDirector/PDMR Shareholding
21st Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSFutura files for Further Pre-Submission meeting
16th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 202011:05 amRNSSecond Price Monitoring Extn
16th Apr 202011:00 amRNSPrice Monitoring Extension
7th Apr 20204:41 pmRNSSecond Price Monitoring Extn
7th Apr 20204:36 pmRNSPrice Monitoring Extension
6th Apr 20204:41 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
6th Apr 20207:00 amRNSFutura Confirms Receipt of US FDA Minutes
1st Apr 20207:00 amRNSFull Year Results for the year ended 31 Dec 2019
16th Mar 20207:00 amRNSNotice of Results
5th Mar 20207:00 amRNSFutura to Update on MED3000 at Investor Seminar
27th Feb 20209:37 amRNSHolding(s) in Company
17th Feb 202012:53 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNSUpdate on positive EU regulatory discussions
30th Jan 20207:00 amRNSTotal Voting Rights
22nd Jan 20202:33 pmRNSRemuneration of NED and Total Voting Rights
21st Jan 20202:17 pmRNSHolding(s) in Company
21st Jan 20201:44 pmRNSHolding(s) in Company
17th Jan 202012:12 pmRNSGM Statement
7th Jan 202011:05 amRNSSecond Price Monitoring Extn
7th Jan 202011:00 amRNSPrice Monitoring Extension
27th Dec 20197:00 amRNSPosting of Circular and Notice of General Meeting
23rd Dec 20197:00 amRNSResult of Fundraising
20th Dec 20194:40 pmRNSSecond Price Monitoring Extn
20th Dec 20194:35 pmRNSPrice Monitoring Extension
20th Dec 20194:31 pmRNSPrimaryBid Offer
20th Dec 20194:30 pmRNSCorporate Update & Proposed Fundraising
17th Dec 20194:41 pmRNSSecond Price Monitoring Extn
17th Dec 20194:35 pmRNSPrice Monitoring Extension
17th Dec 201911:05 amRNSSecond Price Monitoring Extn
17th Dec 201911:00 amRNSPrice Monitoring Extension
16th Dec 20199:05 amRNSSecond Price Monitoring Extn
16th Dec 20199:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.